The two companies have been working together since 2017, with Takeda pledging $100 million to help GammaDelta advance its cell therapy platform as part of a "build-to-buy" arrangement. The ...

Allogeneic stem cell therapy allows "off the shelf" cells ... In the likely event of an EU licence for the therapy, Takeda will pay a 15 million euro fee to Tigenix. Apart from affecting the ...

The iCAR-T platform was originally developed through a collaboration between Takeda and Kyoto University’s Center for iPS Research and Application (CiRA). The first CAR-T cell therapy created ...

Takeda has agreed to receive an exclusive global licence from Keros Therapeutics to advance the development, manufacture and commercialisation of the investigational activin inhibitor elritercept ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities ... including a midstage CD19 CAR-NK cell therapy, a small molecule known as subasumstat and a peptide agonist ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda said it's laser-focused on six pipeline assets that could each reel in ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Takeda, a global leader in biopharmaceutical innovation ... donor experience solutions to expand personalized healthcare solutions in plasma-based therapy. The offering of data science and ...

Takeda is promoting U.S. chief Julie Kim to be ... The first phase of expansion at the Danish plant just added six new mammalian cell bioreactors, and the next phase is being backed by $1.6 ...

Global Cell Therapy market is driven by increasing demand for advanced therapies in oncology, regenerative medicine, and immunology. The market's expansion is also fueled by continuous innovations in ...